$SHPH
Shuttle Pharmaceuticals Holdings, Inc. Stock $shph

$shph Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000149315224010822 Filed on March 21, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue		$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin		$850.2K	$2.375M
YoY Change		182.39%	122.87%
% of Gross Profit
Research & Development	$586.1K	$432.6K	$3.517M
YoY Change	-42.02%	-1.61%	136.28%
% of Gross Profit
Depreciation & Amortization	$1.912K	$1.980K	$6.811K
YoY Change	28.49%	32.89%	14.05%
% of Gross Profit
Operating Expenses	$1.385M	$1.283M	$5.892M
YoY Change	-10.35%	73.17%	130.69%
Operating Profit	-$1.385M		-$5.892M
YoY Change	-10.35%		130.69%
Interest Expense		-$357.7K	-$118.9K
YoY Change		3434.39%	-86.43%
% of Operating Profit
Other Income/Expense, Net	-$346.2K	$0.00	-$700.3K
YoY Change	-160.77%		47.7%
Pretax Income		-$1.641M	-$6.593M
YoY Change		118.47%	117.69%
Income Tax
% Of Pretax Income
Net Earnings	-$1.700M	-$1.641M	-$6.600M
YoY Change	74.34%	118.47%	117.93%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.10		-$0.44
Diluted Earnings Per Share	-$0.10	-$0.10	-$0.44
COMMON SHARES
Basic Shares Outstanding	16.79M shares	16.00M shares	14.92M shares
Diluted Shares Outstanding	16.57M shares		14.92M shares

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments		$5.464M	$5.464M
YoY Change		-35.09%	-35.09%
Cash & Equivalents	$1.399M	$2.576M	$2.576M
Short-Term Investments		$2.887M	$2.887M
Other Short-Term Assets	$81.53K	$114.5K	$114.5K
YoY Change	-59.23%	-28.97%	-28.97%
Inventory
Prepaid Expenses	$129.6K	$114.5K
Receivables		$14.90K	$14.90K
Other Receivables		$0.00	$0.00
Total Short-Term Assets	$4.411M	$5.593M	$5.593M
YoY Change	-57.47%	-34.8%	-34.8%
LONG-TERM ASSETS
Property, Plant & Equipment	$22.92K	$24.83K	$358.7K
YoY Change	106.37%	97.16%	422.09%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets			$0.00
YoY Change			-100.0%
Total Long-Term Assets	$342.9K	$358.7K	$358.7K
YoY Change	430.68%	377.07%	377.03%
TOTAL ASSETS
Total Short-Term Assets	$4.411M	$5.593M	$5.593M
Total Long-Term Assets	$342.9K	$358.7K	$358.7K
Total Assets	$4.754M	$5.952M	$5.952M
YoY Change	-54.45%	-31.22%	-31.22%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable		$282.9K	$282.9K
YoY Change		142.28%	142.28%
Accrued Expenses		$163.4K	$163.4K
YoY Change		-5.81%	-5.81%
Deferred Revenue
YoY Change
Short-Term Debt		$0.00	$0.00
YoY Change		-100.0%	-100.0%
Long-Term Debt Due		$596.0K	$596.0K
YoY Change
Total Short-Term Liabilities	$1.489M	$1.042M	$1.042M
YoY Change	7.26%	6.82%	6.82%
LONG-TERM LIABILITIES
Long-Term Debt		$135.1K	$135.1K
YoY Change
Other Long-Term Liabilities		$718.6K	$718.6K
YoY Change
Total Long-Term Liabilities		$853.7K	$853.7K
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.489M	$1.042M	$1.042M
Total Long-Term Liabilities		$853.7K	$853.7K
Total Liabilities	$1.992M	$1.896M	$1.896M
YoY Change	-43.56%	94.32%	94.32%
SHAREHOLDERS EQUITY
Retained Earnings	-$17.22M	-$15.49M
YoY Change	74.45%	74.12%
Common Stock	$168.00	$161.00
YoY Change	22.63%	-100.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$2.761M	$4.056M	$4.056M
YoY Change
Total Liabilities & Shareholders Equity	$4.754M	$5.952M	$5.952M
YoY Change	-54.45%	-31.22%	-31.22%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$1.700M	-$1.641M	-$6.600M
YoY Change	74.34%	118.47%	117.93%
Depreciation, Depletion And Amortization	$1.912K	$1.980K	$6.811K
YoY Change	28.49%	32.89%	14.05%
Cash From Operating Activities	-$1.239M	-$1.062M	-$5.581M
YoY Change	-7.39%	56.24%	105.91%
INVESTING ACTIVITIES
Capital Expenditures			$19.05K
YoY Change
Acquisitions
YoY Change
Other Investing Activities		$87.03K	-$2.811M
YoY Change
Cash From Investing Activities	$101.3K	$87.04K	-$2.830M
YoY Change	-103.43%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-$40.00K	-334.4K	$2.570M
YoY Change	-101.31%	1334.18%	-75.81%
NET CHANGE
Cash From Operating Activities	-$1.239M	-1.062M	-$5.581M
Cash From Investing Activities	$101.3K	87.04K	-$2.830M
Cash From Financing Activities	-$40.00K	-334.4K	$2.570M
Net Change In Cash	-$1.178M	-1.310M	-$5.841M
YoY Change	-5.62%	86.24%	-173.82%
FREE CASH FLOW
Cash From Operating Activities	-$1.239M	-$1.062M	-$5.581M
Capital Expenditures			$19.05K
Free Cash Flow			-$5.600M
YoY Change			106.61%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent		usd
CY2022Q4	us-gaap	Interest Receivable Current InterestReceivableCurrent		usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent		usd
CY2022Q4	SHPH	Convertible Note Payable Current ConvertibleNotePayableCurrent		usd
CY2022Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable		usd
CY2022Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent		usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent		usd
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2023	us-gaap	Revenues Revenues		usd
CY2022	us-gaap	Revenues Revenues		usd
CY2022	us-gaap	Investment Income Interest InvestmentIncomeInterest		usd
CY2022	SHPH	Finance Fee FinanceFee		usd
CY2022	us-gaap	Gain Loss On Sale Of Investments GainLossOnSaleOfInvestments		usd
CY2022	us-gaap	Marketable Securities Gain Loss Excluding Other Than Temporary Impairments MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments		usd
CY2022	SHPH	Loss On Settlement Of Convertible Debt LossOnSettlementOfConvertibleDebt		usd
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
CY2023	SHPH	Gain On Forgiveness Of Note Payable GainOnForgivenessOfNotePayable		usd
CY2023	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact		usd
CY2022	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross		usd
CY2023	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross		usd
CY2022	us-gaap	Gain Loss On Sale Of Investments GainLossOnSaleOfInvestments		usd
CY2022	us-gaap	Marketable Securities Gain Loss Excluding Other Than Temporary Impairments MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments		usd
CY2022	SHPH	Accrued Interest Settled With Common Stock AccruedInterestSettledWithCommonStock		usd
CY2022	SHPH	Loss On Settlement Of Convertible Debt LossOnSettlementOfConvertibleDebt		usd
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
CY2023	SHPH	Gain On Forgiveness Of Note Payable GainOnForgivenessOfNotePayable		usd
CY2023	us-gaap	Debt Securities Gain Loss DebtSecuritiesGainLoss		usd
CY2022	us-gaap	Increase Decrease In Accrued Interest Receivable Net IncreaseDecreaseInAccruedInterestReceivableNet		usd
CY2022	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets		usd
CY2022	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities		usd
CY2022	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities		usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment		usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities		usd
CY2023	SHPH	Proceeds From Issuance Of Common Stock And Exercise Of Warrants ProceedsFromIssuanceOfCommonStockAndExerciseOfWarrants		usd
CY2023	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt		usd
CY2022	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts		usd
CY2022	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt		usd
CY2023	us-gaap	Income Taxes Paid IncomeTaxesPaid		usd
CY2022	us-gaap	Income Taxes Paid IncomeTaxesPaid		usd
CY2023	SHPH	Common Stock Issued For Conversion Of Accrued Interest CommonStockIssuedForConversionOfAccruedInterest		usd
CY2023	SHPH	Common Stock Issued For Exercise Of Warrants With Settlement Of Notes Payable CommonStockIssuedForExerciseOfWarrantsWithSettlementOfNotesPayable		usd
CY2023	SHPH	Common Stock Issued For Dividend Payable CommonStockIssuedForDividendPayable		usd
CY2022	SHPH	Initial Recognition Of Right Of Use Asset And Liability InitialRecognitionOfRightOfUseAssetAndLiability		usd
CY2022	us-gaap	Marketable Securities Gain Loss Excluding Other Than Temporary Impairments MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments		usd
CY2022	us-gaap	Variable Lease Cost VariableLeaseCost		usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability		usd
CY2022	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential		usd
CY2022	SHPH	Shortfall Of Stock Compensation Expense ShortfallOfStockCompensationExpense		usd
CY2022	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments		usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2023Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment		usd
CY2022Q4	SHPH	Deferred Tax Assetsbased Compensation DeferredTaxAssetsbasedCompensation		usd
CY2022Q4	SHPH	Deferred Tax Assets Lease Liabilities DeferredTaxAssetsLeaseLiabilities		usd
CY2022Q4	SHPH	Deferred Tax Liabilities Fair Market Value DeferredTaxLiabilitiesFairMarketValue		usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Prepaid Expenses DeferredTaxLiabilitiesPrepaidExpenses		usd
CY2022Q4	SHPH	Deferred Tax Liabilities Finite Lived Assets DeferredTaxLiabilitiesFiniteLivedAssets		usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities		usd
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2022	SHPH	Effective Income Tax Rate Reconciliation Short Fall Of Stock Compensation Expense EffectiveIncomeTaxRateReconciliationShortFallOfStockCompensationExpense		pure
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	City Area Code CityAreaCode	(240)
CY2023	dei	Local Phone Number LocalPhoneNumber	403-4212
CY2023	dei	Security12b Title Security12bTitle	Common Stock
CY2023	dei	Trading Symbol TradingSymbol	SHPH
CY2023	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-41488
CY2023	dei	Entity Registrant Name EntityRegistrantName	Shuttle Pharmaceuticals Holdings, Inc.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	82-5089826
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	401 Professional Drive
CY2023	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 260
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Gaithersburg
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	MD
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	20879
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	true
CY2023	dei	Document Fin Stmt Restatement Recovery Analysis Flag DocumentFinStmtRestatementRecoveryAnalysisFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	11712797	usd
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	16794893	shares
CY2023	dei	Auditor Firm AuditorFirmId	686
CY2023	dei	Auditor Name AuditorName	FORVIS, LLP
CY2023	dei	Auditor Location AuditorLocation	Atlanta, GA
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2576416	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8417203	usd
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	114473	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	161148	usd
CY2023Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	2887215	usd
CY2023Q4	us-gaap	Interest Receivable Current InterestReceivableCurrent	14901	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	5593005	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	8578351	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	121685	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	114875	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	24827	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	12592	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	6480	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	333904	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	56122	usd
CY2023Q4	us-gaap	Assets Assets	5951736	usd
CY2022Q4	us-gaap	Assets Assets	8653545	usd
CY2023Q4	SHPH	Convertible Note Payable Current ConvertibleNotePayableCurrent	595999	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	52479	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	62823	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1042237	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	975676	usd
CY2023Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	135089	usd
CY2023Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	414512	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	304127	usd
CY2023Q4	us-gaap	Liabilities Liabilities	1895965	usd
CY2022Q4	us-gaap	Liabilities Liabilities	975676	usd
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00001
CY2023Q4	us-gaap	Preferred Stock Liquidation Preference PreferredStockLiquidationPreference	1000
CY2022Q4	us-gaap	Preferred Stock Liquidation Preference PreferredStockLiquidationPreference	1000
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	16069320	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	16069320	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	13603129	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	13603129	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	161	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	136	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	19543222	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	16572622	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-15487612	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-8894889	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	4055771	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	7677869	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	5951736	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	8653545	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1046854	usd
CY2022	us-gaap	Legal Fees LegalFees	866770	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-5892382	usd
CY2023	us-gaap	Investment Income Interest InvestmentIncomeInterest	79117	usd
CY2023	SHPH	Finance Fee FinanceFee	104245	usd
CY2023	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	2216488	usd
CY2022	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	94025	usd
CY2023	us-gaap	Gain Loss On Sale Of Investments GainLossOnSaleOfInvestments	4970	usd
CY2023	us-gaap	Marketable Securities Gain Loss Excluding Other Than Temporary Impairments MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments	71568	usd
CY2023	SHPH	Loss On Settlement Of Convertible Debt LossOnSettlementOfConvertibleDebt	477221	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	328687	usd
CY2022	SHPH	Gain On Forgiveness Of Note Payable GainOnForgivenessOfNotePayable	73007	usd
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-700341	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-474170	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-6592723	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-3028448	usd
CY2022	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	71009	usd
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-6592723	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-3099457	usd
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	14919484	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	14919484	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	10351046	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	10351046	shares
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.44
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.44
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.29
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.29
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-1628132	usd
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	10008095	usd
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	14098	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	412241	usd
CY2022	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	588524	usd
CY2022	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	576476	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	403956	usd
CY2022	us-gaap	Dividends Preferred Stock DividendsPreferredStock	71009	usd
CY2022	us-gaap	Stock Issued During Period Value Dividend Reinvestment Plan StockIssuedDuringPeriodValueDividendReinvestmentPlan	402068	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-3028448	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	7677869	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	7677869	usd
CY2023	SHPH	Warrants Issuance Fees WarrantsIssuanceFees	8727	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	90816	usd
CY2023	SHPH	Stock Issued During Period Value Conversion Of Accrued Interest And Principal StockIssuedDuringPeriodValueConversionOfAccruedInterestAndPrincipal	2697849	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	181960	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-6592723	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	4055771	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-6592723	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-3028448	usd
CY2023	us-gaap	Depreciation Depreciation	6811	usd
CY2022	us-gaap	Depreciation Depreciation	5972	usd
CY2023	SHPH	Change In Fair Value Of Derivative Liability ChangeInFairValueOfDerivativeLiability	2216488	usd
CY2022	SHPH	Change In Fair Value Of Derivative Liability ChangeInFairValueOfDerivativeLiability	94025	usd
CY2023	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	2123049	usd
CY2022	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	885505	usd
CY2023	us-gaap	Gain Loss On Sale Of Investments GainLossOnSaleOfInvestments	4970	usd
CY2023	us-gaap	Marketable Securities Gain Loss Excluding Other Than Temporary Impairments MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments	71568	usd
CY2023	SHPH	Accrued Interest Settled With Common Stock AccruedInterestSettledWithCommonStock	294927	usd
CY2023	SHPH	Loss On Settlement Of Convertible Debt LossOnSettlementOfConvertibleDebt	477221	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	328687	usd
CY2022	SHPH	Gain On Forgiveness Of Note Payable GainOnForgivenessOfNotePayable	73007	usd
CY2022	us-gaap	Debt Securities Gain Loss DebtSecuritiesGainLoss	-12625	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	181960	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	403956	usd
CY2023	us-gaap	Increase Decrease In Accrued Interest Receivable Net IncreaseDecreaseInAccruedInterestReceivableNet	14901	usd
CY2023	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-46675	usd
CY2022	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	156282	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	166115	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-382881	usd
CY2023	us-gaap	Increase Decrease In Due To Related Parties Current IncreaseDecreaseInDueToRelatedPartiesCurrent	-12054	usd
CY2022	us-gaap	Increase Decrease In Due To Related Parties Current IncreaseDecreaseInDueToRelatedPartiesCurrent	12500	usd
CY2023	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	110453	usd
CY2022	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	-13177	usd
CY2023	SHPH	Increase Decrease In Accrued Interest Payable Related Parties IncreaseDecreaseInAccruedInterestPayableRelatedParties	-98135	usd
CY2022	SHPH	Increase Decrease In Accrued Interest Payable Related Parties IncreaseDecreaseInAccruedInterestPayableRelatedParties	51188	usd
CY2023	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-6480	usd
CY2023	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	16001	usd
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-5693	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-5581147	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2710454	usd
CY2023	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	2998572	usd
CY2023	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	187895	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	19046	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2829723	usd
CY2022	SHPH	Proceeds From Issuance Of Common Stock And Exercise Of Warrants ProceedsFromIssuanceOfCommonStockAndExerciseOfWarrants	10022193	usd
CY2022	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	50000	usd
CY2023	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	685473	usd
CY2022	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	50000	usd
CY2023	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	3935000	usd
CY2022	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	600715	usd
CY2023	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	345000	usd
CY2023	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	334444	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2570083	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	10622908	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-5840787	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	7912454	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	8417203	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	504749	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	2576416	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	8417203	usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet	164807	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	39201	usd
CY2022	SHPH	Common Stock Issued For Conversion Of Accrued Interest CommonStockIssuedForConversionOfAccruedInterest	16340	usd
CY2023	SHPH	Common Stock Issued For Settlement Of Debt CommonStockIssuedForSettlementOfDebt	2697849	usd
CY2022	SHPH	Common Stock Issued For Settlement Of Debt CommonStockIssuedForSettlementOfDebt	588524	usd
CY2022	SHPH	Common Stock Issued For Exercise Of Warrants With Settlement Of Notes Payable CommonStockIssuedForExerciseOfWarrantsWithSettlementOfNotesPayable	576476	usd
CY2022	SHPH	Common Stock Issued For Dividend Payable CommonStockIssuedForDividendPayable	402068	usd
CY2023	SHPH	Warrants Issuance Fees WarrantsIssuanceFees	8727	usd
CY2022	SHPH	Warrants Issuance Fees WarrantsIssuanceFees	0	usd
CY2023	SHPH	Warrants Issued For Financing Fees WarrantsIssuedForFinancingFees	90816	usd
CY2022	SHPH	Warrants Issued For Financing Fees WarrantsIssuedForFinancingFees	412241	usd
CY2023	SHPH	Initial Recognition Of Right Of Use Asset And Liability InitialRecognitionOfRightOfUseAssetAndLiability	365556	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-6600000	usd
CY2023	SHPH	Working Capital WorkingCapital	-4600000	usd
CY2022Q3	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	10000000.0	usd
CY2023	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p id="xdx_842_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zBWpZS1NGOtd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_864_z51lIHBaxIod">Reclassifications</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications had no effect on the reported results of operations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> </p>
CY2023Q1	us-gaap	Prior Period Reclassification Adjustment PriorPeriodReclassificationAdjustment	89007	usd
CY2023Q2	us-gaap	Prior Period Reclassification Adjustment PriorPeriodReclassificationAdjustment	93708	usd
CY2023Q3	us-gaap	Prior Period Reclassification Adjustment PriorPeriodReclassificationAdjustment	95129	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	538796	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1148712	usd
CY2022	us-gaap	Profit Loss ProfitLoss	1687508	usd
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_848_eus-gaap--UseOfEstimates_zMBrFPqjRAp6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86C_znBsmi9qpX7i">Use of Estimates</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions. The Company bases its estimates and assumptions on current facts, historical experience, and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company’s estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected. Significant estimates are contained in the accompanying consolidated financial statements for the valuation of derivatives and initial measurement of equity-based warrants.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p>
CY2023Q4	us-gaap	Cash Cash	1550098	usd
CY2022Q4	us-gaap	Cash Cash	5411378	usd
CY2023Q4	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	1026318	usd
CY2022Q4	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	3005825	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2576416	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8417203	usd
CY2023Q4	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	usd
CY2023Q4	us-gaap	Cash Uninsured Amount CashUninsuredAmount	1849000	usd
CY2023Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	2887215	usd
CY2023	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	52855	usd
CY2023	us-gaap	Marketable Securities Realized Gain Loss Excluding Other Than Temporary Impairments MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments	4970	usd
CY2023	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	71568	usd
CY2023Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	2887215	usd
CY2023Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	414512	usd
CY2023	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	0	usd
CY2022	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	211455	usd
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2603523	shares
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	356810	shares
CY2023	us-gaap	Lessee Operating Lease Description LesseeOperatingLeaseDescription	The first was for a monthly payment of $6,480, with a security deposit of $6,480 held for the duration of the lease, that commenced on October 1, 2018, with the first payment made on January 1, 2019
CY2023	us-gaap	Payments For Rent PaymentsForRent	6480	usd
CY2023Q4	us-gaap	Deposits Deposits	6480	usd
CY2023	us-gaap	Lease Expiration Date1 LeaseExpirationDate1	2023-10-31
CY2023Q1	SHPH	Estimated Monthly Common Area Maintenance Cost EstimatedMonthlyCommonAreaMaintenanceCost	3300	usd
CY2023Q1	us-gaap	Security Deposit SecurityDeposit	43234	usd
CY2023Q1	us-gaap	Payments For Rent PaymentsForRent	3891	usd
CY2023Q1	SHPH	Common Area Maintenance Cost CommonAreaMaintenanceCost	3315	usd
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	112022	usd
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	70175	usd
CY2023	us-gaap	Variable Lease Cost VariableLeaseCost	24222	usd
CY2023	us-gaap	Sublease Income SubleaseIncome	7819	usd
CY2022	us-gaap	Sublease Income SubleaseIncome	7070	usd
CY2023	us-gaap	Lease Cost LeaseCost	128425	usd
CY2022	us-gaap	Lease Cost LeaseCost	63105	usd
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	95641	usd
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	76248	usd
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	365556	usd
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P4Y8M1D
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P0Y9M18D
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.1048	pure
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.10	pure
CY2022	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	-83975	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	91502	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	94247	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	97074	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	99986	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	68235	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	451044	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	94438	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	356606	usd
CY2021Q4	us-gaap	Debt Instrument Maturity Date Description DebtInstrumentMaturityDateDescription	In December of 2021, the maturity dates of these loans were further extended to June 30, 2022. In July of 2022, the notes were extended to June 30, 2023.
CY2023	us-gaap	Debt Instrument Increase Accrued Interest DebtInstrumentIncreaseAccruedInterest	0	usd
CY2023Q4	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	10000000	usd
CY2023	us-gaap	Interest Expense Debt InterestExpenseDebt	2123049	usd
CY2023Q4	us-gaap	Convertible Debt ConvertibleDebt	2254856	usd
CY2023	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	1523768	usd
CY2023Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	731088	usd
CY2023	us-gaap	Stock Issued During Period Shares Conversion Of Convertible Securities StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities	2380996	shares
CY2022	us-gaap	Stock Issued During Period Shares Conversion Of Convertible Securities StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities	839	shares
CY2022	SHPH	Accrued Interest Value To Issue Shares AccruedInterestValueToIssueShares	16340	usd
CY2022	SHPH	Stock Issued During Period Shares Settlement Of Notes Payable StockIssuedDuringPeriodSharesSettlementOfNotesPayable	147500	shares
CY2022	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	588524	usd
CY2022	SHPH	Common Stock Vesting Of Restricted Stock Unit CommonStockVestingOfRestrictedStockUnit	27989	shares
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	10008095	usd
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	1409771	shares
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	14098	usd
CY2022	SHPH	Stock Issued During Period Shares Exercise Of Warrants StockIssuedDuringPeriodSharesExerciseOfWarrants	857780	shares
CY2022	SHPH	Stock Issued During Period Value Warrants Notes Payable StockIssuedDuringPeriodValueWarrantsNotesPayable	576476	usd
CY2022	SHPH	Stock Issued During Period Shares Conversion Of Preferred Shares StockIssuedDuringPeriodSharesConversionOfPreferredShares	336810	shares
CY2022	SHPH	Stock Issued During Period Shares Conversion Of Dividends StockIssuedDuringPeriodSharesConversionOfDividends	100517	shares
CY2023Q1	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	1018079	shares
CY2023Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	2.35
CY2023	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	1607044	shares
CY2023Q4	SHPH	Share Based Compensation Arrangement By Share Based Payment Award Non Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue	0	usd
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	480325	shares
CY2023Q1	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	1018079	shares
CY2023Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	2.35
CY2023Q1	SHPH	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights Value ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsValue	1189000	usd
CY2023Q4	SHPH	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights Value ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsValue	410660	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Deferred Expense Capitalized Research And Development Costs DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts	3517485	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Deferred Expense Capitalized Research And Development Costs DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts	1488530	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2023	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-1384472	usd
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-635974	usd
CY2023	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-452682	usd
CY2022	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-249847	usd
CY2023	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	-5710	usd
CY2023	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	-240000	usd
CY2023	SHPH	Income Tax Reconciliation Provision Adjustments IncomeTaxReconciliationProvisionAdjustments	286015	usd
CY2022	SHPH	Income Tax Reconciliation Provision Adjustments IncomeTaxReconciliationProvisionAdjustments	66214	usd
CY2023	SHPH	Income Tax Reconciliation Foreign Income Tax Permanent Differences IncomeTaxReconciliationForeignIncomeTaxPermanentDifferences	203909	usd
CY2022	SHPH	Income Tax Reconciliation Foreign Income Tax Permanent Differences IncomeTaxReconciliationForeignIncomeTaxPermanentDifferences	-21355	usd
CY2023	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	1535466	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	924937	usd
CY2023	SHPH	Shortfall Of Stock Compensation Expense ShortfallOfStockCompensationExpense	40674	usd
CY2023	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	16800	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	1727566	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	1173451	usd
CY2022Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	7801	usd
CY2023Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	1197938	usd
CY2022Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	399644	usd
CY2023Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	423915	usd
CY2022Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	215229	usd
CY2023Q4	SHPH	Deferred Tax Assetsbased Compensation DeferredTaxAssetsbasedCompensation	1251	usd
CY2023Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	72140	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	45574	usd
CY2023Q4	SHPH	Deferred Tax Assets Lease Liabilities DeferredTaxAssetsLeaseLiabilities	6326	usd
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	3429136	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	1841698	usd
CY2023Q4	SHPH	Deferred Tax Liabilities Fair Market Value DeferredTaxLiabilitiesFairMarketValue	19943	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Prepaid Expenses DeferredTaxLiabilitiesPrepaidExpenses	30544	usd
CY2023Q4	SHPH	Deferred Tax Liabilities Finite Lived Assets DeferredTaxLiabilitiesFiniteLivedAssets	-2746	usd
CY2023Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	53233	usd
CY2023Q4	SHPH	Deferred Tax Assets Liabilities Net Before Valuation Allowances DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances	3375903	usd
CY2022Q4	SHPH	Deferred Tax Assets Liabilities Net Before Valuation Allowances DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances	1841698	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	3375903	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	1841698	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.069	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.083	pure
CY2023	SHPH	Effective Income Tax Rate Reconciliation Change In Tax Rate EffectiveIncomeTaxRateReconciliationChangeInTaxRate	0.001	pure
CY2022	SHPH	Effective Income Tax Rate Reconciliation Change In Tax Rate EffectiveIncomeTaxRateReconciliationChangeInTaxRate	0.000	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.036	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.028	pure
CY2023	SHPH	Effective Income Tax Rate Reconciliation Return To Provision Adjustments EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments	-0.043	pure
CY2022	SHPH	Effective Income Tax Rate Reconciliation Return To Provision Adjustments EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments	-0.022	pure
CY2023	SHPH	Effective Income Tax Rate Reconciliation Permanent Differences EffectiveIncomeTaxRateReconciliationPermanentDifferences	-0.031	pure
CY2022	SHPH	Effective Income Tax Rate Reconciliation Permanent Differences EffectiveIncomeTaxRateReconciliationPermanentDifferences	0.007	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.232	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.305	pure
CY2023	SHPH	Effective Income Tax Rate Reconciliation Short Fall Of Stock Compensation Expense EffectiveIncomeTaxRateReconciliationShortFallOfStockCompensationExpense	-0.006	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.004	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.001	pure
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.000	pure
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.000	pure
CY2023	SHPH	Deferred Tax Assets Operating Loss Carried Forward DeferredTaxAssetsOperatingLossCarriedForward	P20Y
CY2023	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	6036599	usd
CY2023	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	5933889	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Leases EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLeases	0.80	pure
CY2023	us-gaap	Income Tax Reconciliation Nondeductible Expense Research And Development IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment	360715	usd
CY2023	SHPH	Deferred Tax Assets Operating Loss Carried Forward Future Federal Income DeferredTaxAssetsOperatingLossCarriedForwardFutureFederalIncome	P20Y
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	80000	usd
CY2023Q3	us-gaap	Share Price SharePrice	1.00
CY2023Q3	us-gaap	Debt Instrument Convertible Threshold Consecutive Trading Days1 DebtInstrumentConvertibleThresholdConsecutiveTradingDays1	30

Files In Submission

Name	View Source	Status
0001493152-24-010822-index-headers.html	Edgar Link	pending
0001493152-24-010822-index.html	Edgar Link	pending
0001493152-24-010822.txt	Edgar Link	pending
0001493152-24-010822-xbrl.zip	Edgar Link	pending
ex21.htm	Edgar Link	pending
ex23-1.htm	Edgar Link	pending
ex23-2.htm	Edgar Link	pending
ex23-2_001.jpg	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-k.htm	Edgar Link	pending
form10-k_001.jpg	Edgar Link	pending
form10-k_002.jpg	Edgar Link	pending
form10-k_003.jpg	Edgar Link	pending
form10-k_004.jpg	Edgar Link	pending
form10-k_005.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
form10-k_htm.xml	Edgar Link	completed
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
shph-20231231.xsd	Edgar Link	pending
shph-20231231_lab.xml	Edgar Link	unprocessable
shph-20231231_pre.xml	Edgar Link	unprocessable
shph-20231231_cal.xml	Edgar Link	unprocessable
shph-20231231_def.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SHPH
Shuttle Pharmaceuticals Holdings, Inc. Stock $shph

2024 Q1 Form 10-K Financial Statement

#000149315224010822 Filed on March 21, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SHPH Shuttle Pharmaceuticals Holdings, Inc. Stock $shph

2024 Q1 Form 10-K Financial Statement

#000149315224010822 Filed on March 21, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SHPH
Shuttle Pharmaceuticals Holdings, Inc. Stock $shph